SURE

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

Retrieved on: 
Wednesday, February 9, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Industry, Hematology, Multimedia, Hives, Immunoglobulin E, Doctor of Philosophy, Allergen, Asthma, Solution, Immortalised cell line, Patient, Conditional sentence, Adult, Genome, Omalizumab, Chromatin, Allergy, Mab, A-DNA, SURE, Vaccine, Partnership, Transgene, Ageing, Generic drug, Pharmaceutical industry, Selexis SA, Generium, SELEXIS SA, GENERIUM

Selexis SA and Generium JSC today announced that Genolar, Generiums biosimilar of omalizumab, is now commercially available in Russia for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria.

Key Points: 
  • Selexis SA and Generium JSC today announced that Genolar, Generiums biosimilar of omalizumab, is now commercially available in Russia for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria.
  • Genolar is the third Selexis SUREtechnology Platform-generated biosimilar to reach the market under commercial license agreements between Generium and Selexis.
  • It marks the ninth marketed biologic product to leverage Selexis SUREtechnology Platform.
  • Atopic asthma is the most common form of asthma, affecting 7090% of children and about 50% of adult sufferers.

InventHelp Inventor Develops Device to Clean Shoes Before Entering a Home (KXX-307)

Retrieved on: 
Tuesday, November 23, 2021
DEPT, Sale, Ninth Street, Safety, Multimedia, SURE, Patent, SARS, Shoe, CLEAN, 3D printing

My design ensures that your shoes are free from contaminants such as dirt, pet waste, yard chemicals and germs such as SARS."

Key Points: 
  • My design ensures that your shoes are free from contaminants such as dirt, pet waste, yard chemicals and germs such as SARS."
  • The invention provides an effective way to sanitize the bottom of shoes when entering a home.
  • In doing so, it prevents shoes from tracking dirt and germs inside.
  • As a result, it eliminates the need to remove your shoes and it enhances comfort and safety.

Chembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) Ltd

Retrieved on: 
Monday, November 22, 2021
Transfer, Sale, Technology, Hearing, Hospital, Diagnosis, Infection, COVID-19, Record, GLOBE, Marketing, SURE, Vertically transmitted infection, Â, DPP, Government, HIV, Pharmaceutical industry, Vaccine, Video game console

HAUPPAUGE, N.Y., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostic Systems Inc. (Chembio), a subsidiary of Chembio Diagnostics, Inc. (Nasdaq: CEMI), received an international arbitration award Thursday, November 18, 2021 against BioSure (UK) Ltd, Chembios former UK distributor of HIV self-tests.

Key Points: 
  • HAUPPAUGE, N.Y., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostic Systems Inc. (Chembio), a subsidiary of Chembio Diagnostics, Inc. (Nasdaq: CEMI), received an international arbitration award Thursday, November 18, 2021 against BioSure (UK) Ltd, Chembios former UK distributor of HIV self-tests.
  • In April 2014, Chembio and BioSure entered into a distribution agreement under which BioSure was licensed the right to sell bundled products in the UK containing Chembios SURE CHECK HIV pouched tests.
  • On September 16, 2019, Chembio initiated arbitration in New York, USA alleging BioSure breached the distribution agreement, misappropriated Chembios trade secrets, and engaged in other unlawful conduct.
  • In addition to the monetary award, BioSure has been ordered to immediately:
    Stop making, using, offering for sale, or selling the BioSure HIV Self Test.

SURE Retractors Inc. Raises Over $1.5M of Series Seed Preferred Stock

Retrieved on: 
Thursday, September 2, 2021
Sure, Duane Morris, LLC, Government, Pressure, Acquisition, Surgeon, United States Department of Defense, Physician, FINRA, SURE, CVE, R, Wilson Sonsini Goodrich & Rosati, Awareness, NEWS, Infection, Innovation, Risk, Goal, U.S. government and smoking cessation, Patient, CEO, SIPC, COVID-19, Technology, Pharmaceutical industry, Health insurance

SURE Retractors Inc. ("SURE"), a medical devices company founded in Glasgow, Scotland, has raised over $1.5M in its series seed round to develop and launch the SURE retractor product pipeline.

Key Points: 
  • SURE Retractors Inc. ("SURE"), a medical devices company founded in Glasgow, Scotland, has raised over $1.5M in its series seed round to develop and launch the SURE retractor product pipeline.
  • SURE previously formed a US Advisory Board which will assist the company in bringing its revolutionary technology to the US market.
  • SURE has already proven the concept of single-use sterile radiolucent retractors with positive feedback from a number of surgeons.
  • SURE was represented by Wilson Sonsini Goodrich & Rosati in the US and Fraser Morrison of McKee Campbell Morrison Ltd. in Glasgow.

InventHelp Inventor Develops Vehicle Accessory to Safely Reduce Glare (CBA-3974)

Retrieved on: 
Tuesday, August 24, 2021
Sale, Ninth Street, Multimedia, SURE, Safety, Telescopic sight

PITTSBURGH, Aug. 24, 2021 /PRNewswire/ -- "I wanted to create a safe and simple way to reduce sunlight glare while driving during the day and headlight glare at night," said an inventor, from Columbia, S.C., "so I invented the SURE SIGHT.

Key Points: 
  • PITTSBURGH, Aug. 24, 2021 /PRNewswire/ -- "I wanted to create a safe and simple way to reduce sunlight glare while driving during the day and headlight glare at night," said an inventor, from Columbia, S.C., "so I invented the SURE SIGHT.
  • The invention provides an effective way to protect the eyes against sunlight glare while driving.
  • The invention features an adaptable and adjustable design that is convenient and easy to use so it is ideal for vehicle owners and professional drivers.
  • The original design was submitted to the Columbia sales office of InventHelp.